Shares of NASDAQ:TXG opened at $10.34 on Friday. The stock has a market capitalization of $1.26 billion, a P/E ratio of -6.80 and a beta of 1.93. 10x Genomics has a 1-year low of $9.27 and a 1 ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used ...

10x Genomics, Inc., a life science technology ... and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics and Syncell streamline cutting-edge ... Concentrations of p-tau217 can signal the accumulation of proteins that cause Alzheimer’s years before the onset of cognitive symptoms ...

Small molecule drugs don’t display enough surface area to bind exterior protein surfaces. This is why they presently only target about 800 proteins in the human genome. Synthesizing larger organic ...